Furthermore, in glioma with the IDH mutation, 1p/19q non-codel, gender (female or male), age (>60 or ≤60), and type of glioma (astrocytoma or oligodendroglioma), there was also a noteworthy association between the overexpression of SUMF1 and adverse outcomes relating to DSS and disease progression in patients (Figures 4, 5). Here, SUMF1 is linked to astrocytoma (excluding glioblastoma).